GlassScriptPhysician profile
Iqra Iqbal
NPI 1104353614
$755.74
in general payments reported to CMS, 2019-2025
8 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2023: $14.11 · 2024: $14.20 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $224.83 | 2025 | |
| Genentech USA, INC. | $133.21 | 2019 | |
| Medtronic, INC. | $130.80 | 2025 | Minimed 780g |
| Pfizer INC. | $115.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $84.01 | 2019 | |
| Dexcom, INC. | $31.61 | 2024-2025 | Dexcom G6 Transmitter |
| Carl Zeiss Meditec USA, INC. | $21.79 | 2025 | |
| Smith+Nephew, INC. | $14.11 | 2023 | Regranex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqra Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.